Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

13.17 -0.44 (-3.23%)
Streaming Delayed Price Updated: 9:51 AM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
27 28 Next >
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ: SRPT).... 
Via Benzinga
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta
The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets. 
Via Investor's Business Daily
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
From Sarepta Therapeutics, Inc.
Via Business Wire
Analyst Expectations For Sarepta Therapeutics's Future
Via Benzinga
Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights
Via Benzinga
Unveiling 15 Analyst Insights On Sarepta Therapeutics
Via Benzinga
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript
SRPT earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics
Via Benzinga
Unveiling 26 Analyst Insights On Sarepta Therapeutics
Via Benzinga
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... 
Via Benzinga
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
2 High-Flying Growth Stocks With Massive Upside Potential
These innovative drugmakers have potential catalysts ahead. 
Via The Motley Fool
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
These two could become direct competitors relatively soon. 
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy 
Via MarketBeat
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
From Sarepta Therapeutics, Inc.
Via Business Wire
These 2 Biotech Stocks Are Set to Soar
Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins. 
Via The Motley Fool
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
From Sarepta Therapeutics, Inc.
Via Business Wire
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful... 
Via Benzinga
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results. 
Via Investor's Business Daily
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.